This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuan, H.
Right arrow Articles by Schlegel, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, H.
Right arrow Articles by Schlegel, R.

 Previous Article  |  Next Article 

Journal of Virology, September 2001, p. 7848-7853, Vol. 75, No. 17
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.17.7848-7853.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Immunization with a Pentameric L1 Fusion Protein Protects against Papillomavirus Infection

Hang Yuan,1 Patricia A. Estes,2 Yan Chen,1 Joseph Newsome,1 Vanessa A. Olcese,1 Robert L. Garcea,2 and Richard Schlegel1,*

Department of Pathology, Georgetown University School of Medicine, Washington, D.C. 20007,1 and Section of Pediatric Hematology/Oncology, University of Colorado School of Medicine, Denver, Colorado 802622

Received 22 January 2001/Accepted 23 May 2001

The prophylactic papillomavirus vaccines currently in clinical trials are composed of viral L1 capsid protein that is synthesized in eukaryotic expression systems and purified in the form of virus-like particles (VLPs). To evaluate whether VLPs are necessary for effective vaccination, we expressed the L1 protein as a glutathione S-transferase (GST) fusion protein in Escherichia coli and assayed its immunogenic activity in an established canine oral papillomavirus (COPV) model that previously validated the efficacy of VLP vaccines. The GST-COPV L1 fusion protein formed pentamers, but these capsomere-like structures did not assemble into VLPs. Despite the lack of VLP formation, the GST-COPV L1 protein retained its native conformation as determined by reactivity with conformation-specific anti-COPV antibodies. Most importantly, the GST-COPV L1 pentamers completely protected dogs from high-dose viral infection of their oral mucosa. L1 fusion proteins expressed in bacteria represent an economical alternative to VLPs as a human papillomavirus vaccine.

* Corresponding author. Mailing address: Department of Pathology, Georgetown University School of Medicine, 3900 Reservoir Rd., Washington, DC 20007. Phone: (202) 687-1704. Fax: (202) 687-8934. E-mail: schleger{at}georgetown.edu.

Journal of Virology, September 2001, p. 7848-7853, Vol. 75, No. 17
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.17.7848-7853.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Schadlich, L., Senger, T., Gerlach, B., Mucke, N., Klein, C., Bravo, I. G., Muller, M., Gissmann, L. (2009). Analysis of Modified Human Papillomavirus Type 16 L1 Capsomeres: the Ability To Assemble into Larger Particles Correlates with Higher Immunogenicity. J. Virol. 83: 7690-7705 [Abstract] [Full Text]  
  • Lange, C. E., Tobler, K., Favrot, C., Muller, M., Nothling, J. O., Ackermann, M. (2009). Detection of Antibodies against Epidermodysplasia Verruciformis-Associated Canine Papillomavirus 3 in Sera of Dogs from Europe and Africa by Enzyme-Linked Immunosorbent Assay. CVI 16: 66-72 [Abstract] [Full Text]  
  • Thones, N., Herreiner, A., Schadlich, L., Piuko, K., Muller, M. (2008). A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response. J. Virol. 82: 5472-5485 [Abstract] [Full Text]  
  • Bian, T., Wang, Y., Lu, Z., Ye, Z., Zhao, L., Ren, J., Zhang, H., Ruan, L., Tian, H. (2008). Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Molecular Cancer Therapeutics 7: 1329-1335 [Abstract] [Full Text]  
  • Rizk, R. Z., Christensen, N. D., Michael, K. M., Muller, M., Sehr, P., Waterboer, T., Pawlita, M. (2008). Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J. Gen. Virol. 89: 117-129 [Abstract] [Full Text]  
  • Disbrow, G. L., Baege, A. C., Kierpiec, K. A., Yuan, H., Centeno, J. A., Thibodeaux, C. A., Hartmann, D., Schlegel, R. (2005). Dihydroartemisinin Is Cytotoxic to Papillomavirus-Expressing Epithelial Cells In vitro and In vivo. Cancer Res. 65: 10854-10861 [Abstract] [Full Text]  
  • Orozco, J. J., Carter, J. J., Koutsky, L. A., Galloway, D. A. (2005). Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 Capsomers. J. Virol. 79: 9503-9514 [Abstract] [Full Text]  
  • Biemelt, S., Sonnewald, U., Galmbacher, P., Willmitzer, L., Muller, M. (2003). Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants. J. Virol. 77: 9211-9220 [Abstract] [Full Text]  
  • Devaraj, K., Gillison, M. L., Wu, T.-C. (2003). DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. CROBM 14: 345-362 [Abstract] [Full Text]  
  • Varsani, A., Williamson, A.-L., de Villiers, D., Becker, I., Christensen, N. D., Rybicki, E. P. (2003). Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16. J. Virol. 77: 8386-8393 [Abstract] [Full Text]  
  • Lowy, D. R., Frazer, I. H. (2003). Chapter 16: Prophylactic Human Papillomavirus Vaccines. J Natl Cancer Inst Monogr 2003: 111-116 [Abstract] [Full Text]  
  • Ohlschlager, P., Osen, W., Dell, K., Faath, S., Garcea, R. L., Jochmus, I., Muller, M., Pawlita, M., Schafer, K., Sehr, P., Staib, C., Sutter, G., Gissmann, L. (2003). Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Specific Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice. J. Virol. 77: 4635-4645 [Abstract] [Full Text]  
  • Finnen, R. L., Erickson, K. D., Chen, X. S., Garcea, R. L. (2003). Interactions between Papillomavirus L1 and L2 Capsid Proteins. J. Virol. 77: 4818-4826 [Abstract] [Full Text]  
  • Peh, W. L., Middleton, K., Christensen, N., Nicholls, P., Egawa, K., Sotlar, K., Brandsma, J., Percival, A., Lewis, J., Liu, W. J., Doorbar, J. (2002). Life Cycle Heterogeneity in Animal Models of Human Papillomavirus-Associated Disease. J. Virol. 76: 10401-10416 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»